Sign In
Buy ABCL
$5.72
-0.410 (-6.69%)
At Close: Jun 03, 2026
AbCellera Biologics Inc. (ABCL) Q4 2024 Earnings Call Transcript
11:26pm, Thursday, 27'th Feb 2025
AbCellera Biologics Inc. (NASDAQ:ABCL ) Q4 2024 Earnings Conference Call February 27, 2025 5:00 PM ET Company Participants Tryn Stimart - Chief Legal and Compliance Officer Carl Hansen - Chief Executi
AbCellera Biologics Inc. (ABCL) Reports Q4 Loss, Misses Revenue Estimates
07:15pm, Thursday, 27'th Feb 2025
AbCellera Biologics Inc. (ABCL) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.17 per share a year ago.
AbCellera Reports Full Year 2024 Business Results
04:05pm, Thursday, 27'th Feb 2025
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Reports Full Year 2024 Business Results.
AbCellera to Participate at Upcoming Investor Conferences in March
04:05pm, Tuesday, 11'th Feb 2025
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Participate at Upcoming Investor Conferences in March.
AbCellera to Report Full Year 2024 Financial Results on February 27, 2025
04:05pm, Tuesday, 21'st Jan 2025
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Report Full Year 2024 Financial Results on February 27, 2025.
AbCellera Biologics: Still A Concept Stock
04:39pm, Monday, 23'rd Dec 2024
Today, we revisit a somewhat unique developmental company called AbCellera Biologics Inc. The company is moving towards focusing more on its wholly owned candidates off its platform rather than partne
AbCellera to Present at Upcoming Investor Conferences in December and January
04:05pm, Thursday, 21'st Nov 2024
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Present at Upcoming Investor Conferences in December and January.
AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024
10:05am, Thursday, 07'th Nov 2024
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024.
AbCellera Biologics Inc. (ABCL) Q3 2024 Earnings Call Transcript
07:22pm, Monday, 04'th Nov 2024
AbCellera Biologics Inc. (NASDAQ:ABCL ) Q3 2024 Earnings Conference Call November 4, 2024 5:00 PM ET Company Participants Tryn Stimart - Chief Legal and Compliance Officer Carl Hansen - Chief Executiv
AbCellera Biologics Inc. (ABCL) Reports Q3 Loss, Misses Revenue Estimates
06:55pm, Monday, 04'th Nov 2024
AbCellera Biologics Inc. (ABCL) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to loss of $0.10 per share a year ago.
AbCellera to Present at Upcoming Investor Conferences in November 2024
04:05pm, Tuesday, 22'nd Oct 2024
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Present at Upcoming Investor Conferences in November 2024.
AbCellera: A Platform To Pipeline Transition
12:04pm, Monday, 14'th Oct 2024
AbCellera is shifting its focus from a platform biotech company to its internal drug pipeline. The company's lead asset, ABCL575, comes with a variety of risks, but in our opinion, has a value of a li
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Announces Presentation on T-cell Engager Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024.
AbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024
04:05pm, Thursday, 26'th Sep 2024
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024.
AbCellera: A Waiting Game With High Uncertainty
04:43am, Friday, 23'rd Aug 2024
AbCellera's Q2 2024 revenue declined by 27% year-over-year to $7.3 million. The company's net loss widened to $36.9 million due to increased R&D expenses. AbCellera's cash and marketable securities to
